Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Ryousei Sasaki, MD, PhD, Wataru Izumita, MD, Takahiro Mine, MD, Maki Asahi, MD, PhD, Yuzo Suzuki, MD, PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yasuhiko Tsukushi, MD, PhD, Yusei Aoki, MD, Shugo Kowata, MD, PhD, Ichiro Hanamura, MD, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2016) 128 (22): 1607.

https://doi.org/10.1182/blood.V128.22.1607.1607

Published: 2016

Journal Articles

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Tatsuo Oyake, MD PhD, Takayuki Masuda, MD PhD, Norifumi Sugawara, MD PhD, Maki Asahi, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD PhD, Shigeki Ito, MD PhD, Yoji Ishida, MDPhD

Blood (2015) 126 (23): 4621.

https://doi.org/10.1182/blood.V126.23.4621.4621

Published: 2015

Journal Articles

A Small-Molecule Suppressant of Survivin YM155 Induces Cell Death Via Proteasomal Degradation of c-Myc in Multiple Myeloma Cells

Shigeki Ito, MD PhD, Maki Asahi, MD, Yoji Ishida, MD, PhD

Blood (2015) 126 (23): 4853.

https://doi.org/10.1182/blood.V126.23.4853.4853

Published: 2015

Journal Articles

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Yasunori Nakagawa, MD, PhD, Takahiro Mine, MD, Ichiro Hanamura, MD, PhD, Maki Asahi, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4954.

https://doi.org/10.1182/blood.V124.21.4954.4954

Published: 2014

Journal Articles

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Shigeki Ito, M.D., Ph.D., Maki Asahi, MD, Ryousei Sasaki, MD, Tatsuo Oyake, M.D., Ph.D., Hideto Tamura, MD, PhD, Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1667.

https://doi.org/10.1182/blood.V122.21.1667.1667

Published: 2013

Journal Articles

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Tatsuo Oyake, M.D., Ph.D., Tadashi Shimoyama, Maki Asahi, Sugawara Norifumi, Ryosei Sasaki, Suzuki Yuzo, Fujishima Yukiteru, Yasuhiko Tsukushi, M.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2186.

https://doi.org/10.1182/blood.V120.21.2186.2186

Published: 2012

NARROW

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

A Small-Molecule Suppressant of Survivin YM155 Induces Cell Death Via Proteasomal Degradation of c-Myc in Multiple Myeloma Cells

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Email alerts

ASH Publications

American Society of Hematology

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

A Small-Molecule Suppressant of Survivin YM155 Induces Cell Death Via Proteasomal Degradation of c-Myc in Multiple Myeloma Cells

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

YM155, a Survivin Suppressant, Induces Cell Death Via Suppression Of c-Myc Expression In Multiple Myeloma Cells

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only